- Home
- BMRN vs EXEL Comparison
BMRN vs EXEL Comparison
Compare BMRN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | EXEL |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 11.1B |
| IPO Year | 1999 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BMRN | EXEL |
|---|---|---|
| Price | $56.93 | $43.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 23 |
| Target Price | ★ $90.15 | $45.45 |
| AVG Volume (30 Days) | 2.0M | ★ 2.2M |
| Earning Date | 02-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.53 | 53.55 |
| EPS | ★ 2.68 | 2.38 |
| Revenue | ★ $3,094,001,000.00 | $2,288,218,000.00 |
| Revenue This Year | $13.42 | $9.74 |
| Revenue Next Year | $10.81 | $12.27 |
| P/E Ratio | $20.97 | ★ $18.63 |
| Revenue Growth | ★ 12.39 | 9.93 |
| 52 Week Low | $50.76 | $31.90 |
| 52 Week High | $73.51 | $49.62 |
Technical Indicators
Market Signals| Indicator | BMRN | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 48.56 |
| Support Level | $54.07 | $43.00 |
| Resistance Level | $58.33 | $45.37 |
| Average True Range (ATR) | 1.68 | 1.64 |
| MACD | -0.30 | -0.14 |
| Stochastic Oscillator | 36.02 | 40.85 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.